Management of hypertrophic cardiomyopathy

Yuhui Zhang; Marianna Adamo; Changhong Zou; Aldostefano Porcari; Daniela Tomasoni; Maddalena Rossi; Marco Merlo; Huihui Liu; Jinxi Wang; Ping Zhou; Marco Metra; Gianfranco Sinagra; Jian Zhang

doi:10.2459/JCM.0000000000001616

Management of hypertrophic cardiomyopathy

J Cardiovasc Med (Hagerstown). 2024 Apr 17. doi: 10.2459/JCM.0000000000001616. Online ahead of print.

Authors

Affiliations

¹ Heart Failure Care Unit, Heart Failure Center, Fuwai Hospital, Chinese Academy of Medical Sciences, Peking Union of Medical College, National Center for Cardiovascular Diseases, Beijing, China.
² Cardiology, ASST Spedali Civili and Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Brescia.
³ Division of Cardiology, Cardiovascular Department, Azienda Sanitaria Universitaria Integrata di Trieste, Trieste, Italy.

PMID: 38625835
DOI: 10.2459/JCM.0000000000001616

Abstract

Hypertrophic cardiomyopathy is an important cause of heart failure and arrhythmias, including sudden death, with a major impact on the healthcare system. Genetic causes and different phenotypes are now increasingly being identified for this condition. In addition, specific medications, such as myosin inhibitors, have been recently shown as potentially able to modify its symptoms, hemodynamic abnormalities and clinical course. Our article aims to provide a comprehensive outline of the epidemiology, diagnosis and treatment of hypertrophic cardiomyopathy in the current era.